Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00233675 · ClinicalTrials.gov registry record · Phase 3
Evaluate the Safety of GABITRIL in Adults With Generalized Anxiety Disorder
A Phase 3 study of General Anxiety Disorder, sponsored by Cephalon.
- Completed
- Registry status
- Phase 3
- Development phase
- 20
- Study locations
NCT00233675: Completed Phase 3 study of General Anxiety Disorder, sponsored by Cephalon.
NCT00233675 is a Phase 3 study of General Anxiety Disorder that has completed, run by Cephalon. The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00233675, a Phase 3 study of General Anxiety Disorder, has completed, sponsored by Cephalon.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 20
- Study locations
Study Summary
To assess the long-term safety and tolerability of tiagabine treatment in patients with generalized anxiety disorder (GAD).
Conditions Studied
Interventions
- DRUG GABITRIL (tiagabine hydrochloride; CEP-6671)
Study Locations (20)
California
- Southwestern Research - Beverly Hills
- Pharmacology Research Institut - Newport Beach
- Pharmacology Research Institut - Northridge
- Pacific Clinical Research Medi - Orange
- Radiant Research San Diego - San Diego
- Affiliated Research Institute - San Diego
New York
- Social Psychiatry Research Ins - Brooklyn
- Fieve Clinical Services, Inc. - New York
- Medical and Behavioral - New York
- Medical Research Network - New York
Florida
- Clinical Neuroscience Solution - Jacksonville
- Clinical Neuroscience Solution - West Palm Beach
Arizona
- Pivotal Research Center - Mesa
Colorado
- Radiant Research Denver - Denver
Connecticut
- University of Connecticut - Farmington
Georgia
- Carman Research - Smyrna
Illinois
- Cunningham Clinical Research - Edwardsville
Trial Details
| Field | Value |
|---|---|
| Start Date | 2003-08 |
| Phase | Phase 3 |
What the finished NCT00233675 record still lists
NCT00233675 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 1 condition, with General Anxiety Disorder appearing as the primary indexed condition, and to 1 intervention - of which GABITRIL (tiagabine hydrochloride; CEP-6671) is the first listed.
NCT00233675 names 20 study sites across 11 states, led by California, New York, Florida.
Frequently Asked Questions
What is clinical trial NCT00233675 about?
NCT00233675 is a clinical study titled "Evaluate the Safety of GABITRIL in Adults With Generalized Anxiety Disorder". To assess the long-term safety and tolerability of tiagabine treatment in patients with generalized anxiety disorder (GAD).
What is the current status of trial NCT00233675?
This trial is currently completed. It is a Phase 3 study. The study started on 2003-08.
What conditions does trial NCT00233675 study?
This clinical trial studies the following conditions: General Anxiety Disorder.
What interventions are being tested in trial NCT00233675?
The interventions under investigation include: GABITRIL (tiagabine hydrochloride; CEP-6671) (DRUG).
Who is sponsoring clinical trial NCT00233675?
This trial is sponsored by Cephalon, which has 64 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00233675 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia